CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 18, 2020—Qiagen has obtained the CE mark for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic for the detection of SARS-CoV-2. The QIAstat-Dx test kit can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients who may have similar symptoms in a single testing run of about one hour.
The panel is a multiplexed nucleic acid test that evaluates samples such as nasopharyngeal swabs obtained from individuals suspected of respiratory tract infections and includes assays targeting two genes used to detect SARS-CoV-2.
Pages: 1 2